Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2
Journal of Antimicrobial Chemotherapy · 02.04.2025 · 80 (4) · 1137-1140
DOI: 10.1093/jac/dkaf045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 17.02.2025. Verfasst von Chaitanya Tellapragada und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden. Hauptthemen laut MEDLINE: Cefepime, Escherichia coli, Anti-Bacterial Agents, Azabicyclo Compounds. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Scilife Pandemic Laboratory Preparedness.
Abstract (Originalsprache)
Objectives
We aimed to investigate the in vitro activity and genetic determinants of decreased susceptibility (DS; MIC > 4 mg/L) to cefepime/zidebactam of carbapenemase-producing Escherichia coli.
Methods
Clinical isolates (N = 150) of carbapenemase-producing E. coli (CP-EC) belonging to seven distinct STs, isolated at a university clinical microbiology laboratory during 2019–2023 in Stockholm, Sweden were included. MICs for cefepime/zidebactam were determined using the broth microdilution method and interpreted using the tentative EUCAST clinical breakpoints (Susceptible; MIC < 4 mg/L; based on cefepime breakpoint). Whole genome sequences of the isolates were analysed with an emphasis on identifying alterations in PBPs 2 and 3.
Results
Of the 150 isolates, 145 (96.6%) isolates had MICs <4 mg/L indicating susceptibility and 5 (3.3%) had MICs >4 mg/L. MICs for zidebactam alone among the five isolates with DS to cefepime/zidebactam were ≥8 mg/L. WGS analysis revealed that these five isolates were NDM-5 producers and belonged to ST405 (n = 1), ST410 (n = 2) and ST648 (n = 2). Presence of four-amino-acid inserts (YRIK/YRIN) in PBP3 was observed in 80/150 (53.3%) isolates, and mutations leading to alterations in PBP2 were observed in 41/150 (27.3%) isolates. Presence of other β-lactamases (CTX-M group) and/or cephalosporinases (blaCMY) did not have an impact on the susceptibility to cefepime/zidebactam. Three of the five isolates with DS had a V522I substitution in PBP2.
Conclusions
Our results indicate that DS to cefepime/zidebactam among clinical isolates of E. coli could arise due to targeted mutations in PBP2.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
- Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.
ORCID-Profile: Chaitanya Tellapragada
Förderung
- Scilife Pandemic Laboratory Preparedness
Zitieren
APA
Tellapragada, C., Dunleavy, C., Jonsson, P., & Giske, C. G. (2025). Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2. Journal of Antimicrobial Chemotherapy, 80(4), 1137-1140. https://doi.org/10.1093/jac/dkaf045
Vancouver
Tellapragada C, Dunleavy C, Jonsson P, Giske CG. Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2. Journal of Antimicrobial Chemotherapy. 2025;80(4):1137-1140. doi:10.1093/jac/dkaf045
BibTeX
@article{Tellapragada2025,
author = {Tellapragada, Chaitanya and Dunleavy, Chantel and Jonsson, Patrik and Giske, Christian G},
title = {Decreased susceptibility to cefepime/zidebactam among carbapenemase-producing Escherichia coli from Stockholm, Sweden with alterations in PBP2},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
volume = {80},
number = {4},
pages = {1137--1140},
doi = {10.1093/jac/dkaf045}
}
EUVIMED